Erica L Mayer

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
  2. ncbi Chemotherapy for metastatic breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:257-72. 2007
  3. ncbi Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast Cancer Res 9:110. 2007
  4. ncbi Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer
    Erica L Mayer
    J Clin Oncol 26:1198-200. 2008
  5. ncbi Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
    E L Mayer
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA
    Breast Cancer Res Treat 117:615-23. 2009
  6. ncbi Breast cancer survivors' perceptions of survivorship care options
    Erica L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    J Clin Oncol 30:158-63. 2012
  7. ncbi Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    Erica L Mayer
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:3526-32. 2010
  8. ncbi SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
    E L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 21:2370-6. 2010
  9. ncbi Congestive heart failure risk in patients with breast cancer treated with bevacizumab
    Toni K Choueiri
    Dana Farber Cancer Institute, 44 Binney St Dana 1230, Boston MA 02115, USA
    J Clin Oncol 29:632-8. 2011
  10. ncbi Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans
    Erica L Mayer
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Hypertension 58:85-92. 2011

Detail Information

Publications11

  1. ncbi Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
    ..This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer...
  2. ncbi Chemotherapy for metastatic breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:257-72. 2007
    ....
  3. ncbi Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast Cancer Res 9:110. 2007
    ..Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population...
  4. ncbi Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer
    Erica L Mayer
    J Clin Oncol 26:1198-200. 2008
  5. ncbi Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
    E L Mayer
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA
    Breast Cancer Res Treat 117:615-23. 2009
    ..This phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC)...
  6. ncbi Breast cancer survivors' perceptions of survivorship care options
    Erica L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    J Clin Oncol 30:158-63. 2012
    ..The objective of this study was to explore survivors' comfort with different clinician types or with a telephone/Internet-based virtual visit as components of survivorship care...
  7. ncbi Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    Erica L Mayer
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:3526-32. 2010
    ..Future trials will continue to explore the contribution of Src inhibition with both chemotherapy and targeted agents...
  8. ncbi SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
    E L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 21:2370-6. 2010
    ..Because laboratory models suggest that combining these approaches might be synergistic, we sought to evaluate the feasibility and efficacy of combining sunitinib with paclitaxel + bevacizumab (PB)...
  9. ncbi Congestive heart failure risk in patients with breast cancer treated with bevacizumab
    Toni K Choueiri
    Dana Farber Cancer Institute, 44 Binney St Dana 1230, Boston MA 02115, USA
    J Clin Oncol 29:632-8. 2011
    ..We performed an up-to-date, comprehensive meta-analysis to determine the risk of serious CHF in patients with breast cancer receiving bevacizumab...
  10. ncbi Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans
    Erica L Mayer
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Hypertension 58:85-92. 2011
    ..Changes in vascular function with tyrosine kinase inhibition are complex and require further study in humans...
  11. ncbi A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
    Erica L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 17:6897-904. 2011
    ..A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive (HR+) advanced breast cancer...